Statera Biopharma (STAB) Short Interest Ratio & Short Volume

Short interest is the volume of Statera Biopharma shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 79,500 shares of STAB short. 0.15% of Statera Biopharma's shares are currently sold short. Learn More on Statera Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. STAB shares currently have a short interest ratio of 23.0. Learn More on Statera Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.15% of Statera Biopharma's floating shares are currently sold short.

0.15% of Statera Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Statera Biopharma: Navidea Biopharmaceuticals, Inc. (0.00%), Evelo Biosciences, Inc. (0.04%), Comera Life Sciences Holdings, Inc. (0.02%), Genocea Biosciences, Inc. (0.33%), Aridis Pharmaceuticals, Inc. (0.00%), Ampio Pharmaceuticals, Inc. (0.01%), Clever Leaves Holdings Inc. (0.52%), eFFECTOR Therapeutics, Inc. (0.13%), OncoSec Medical Incorporated (0.00%), PaxMedica, Inc. (0.01%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), MicroStrategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

Short selling STAB is an investing strategy that aims to generate trading profit from Statera Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Statera Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of STAB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including STAB, twice per month. The most recent reporting period available is May, 31 2025.